Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 108 results for melanoma

  1. Techniques for confirming a diagnosis in people with suspected atypical Spitzoid melanocytic lesions: In people with reported atypical Spitzoid lesions, how effective are fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH) and tests to detect driver mutations compared with histopathological examination alone in predicting disease specific survival? This should be investigated ina prospective diagnostic study. Secondary outcomes should include sensitivity, specificity, accuracy, positive predictive value, disease specific survival and progression free survival.

    with expert review, but it is not always possible to distinguish Spitzoid melanoma from benign Spitzoid melanocytic lesions. Current...

    Research recommendation
    Published
    4 August 2022

  2. Endoscopic radical inguinal lymphadenectomy (IPG398)

    Evidence-based recommendations on endoscopic radical inguinal lymphadenectomy. This involves using an endoscopic device and small incisions to reduce discomfort, scarring and complications associated with inguinal lymph node removal.

    Interventional procedures guidance
    Published
    22 June 2011
    View recommendations

    Sections for IPG398

  3. Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)

    Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.

    Technology appraisal guidance
    Published
    11 January 2023
    View recommendations

    Sections for TA857

  4. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]

    Awaiting development Reference number: GID-TA11275 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema (IPG785)

    Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.

    Interventional procedures guidance
    Published
    16 April 2024
    View recommendations

    Sections for IPG785

  6. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA417

  7. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.

    Technology appraisal guidance
    Published
    28 April 2021
    View recommendations

    Sections for TA692

  8. Vandetanib for treating medullary thyroid cancer (TA550)

    Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.

    Technology appraisal guidance
    Published
    12 December 2018
    View recommendations

    Sections for TA550

  9. Cabozantinib for treating medullary thyroid cancer (TA516)

    Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.

    Technology appraisal guidance
    Published
    28 March 2018
    View recommendations

    Sections for TA516

  10. Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab would be encouraged because it could provide information for future treatment strategies, as would more data on the relative effectiveness of ipilimumab when given as a first-line or second-line treatment.

    Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma Number TA319 Date issued July 2014 Other details

    Research recommendation
    Published
    9 June 2015

  11. Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]

    In development Reference number: GID-TA10577 Expected publication date:  21 April 2021

    Technology appraisal guidance
    In development

  12. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

    Technology appraisal guidance
    Discontinued

  13. Surgical excision for people with lentigo maligna: For people with lentigo maligna (stage 0 in sun damaged skin, usually on the face) how effective is Mohs micrographic surgery, compared with excision with a 0.5 cm clinical margin, in preventing biopsy proven local recurrence at 5 years? This should be investigated in a randomised controlled trial. Secondary outcomes should include cosmetic and functional outcomes.

    adjacent skin. Source guidance details Comes from guidance Melanoma: assessment and management Number NG14 Date issued

    Research recommendation
    Published
    4 August 2022

  14. Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA830

  15. Axxent electronic brachytherapy system for early stage breast cancer (MIB76)

    NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer

    Medtech innovation briefing
    Published
    24 August 2016